Inventiva S.A
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. The company develops Lanifibranor, a novel pan-peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat … Read more
Inventiva S.A (IVEVF) - Total Liabilities
Latest total liabilities as of June 2025: $187.86 Million USD
Based on the latest financial reports, Inventiva S.A (IVEVF) has total liabilities worth $187.86 Million USD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Inventiva S.A - Total Liabilities Trend (2013–2024)
This chart illustrates how Inventiva S.A's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Inventiva S.A Competitors by Total Liabilities
The table below lists competitors of Inventiva S.A ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Surya Roshni Limited
NSE:SURYAROSNI
|
India | ₹9.40 Billion |
|
Gaon Cable
KO:000500
|
Korea | ₩791.47 Billion |
|
Capricorn Energy PLC
PINK:CRNCY
|
USA | $188.60 Million |
|
Ipd Group Ltd
AU:IPG
|
Australia | AU$111.10 Million |
|
Qibu Co Ltd
SHG:603557
|
China | CN¥601.14 Million |
|
Kogan.com Ltd
PINK:KGGNF
|
USA | $171.66 Million |
|
Shang Gong Group Co Ltd B
SHG:900924
|
China | $3.48 Billion |
Liability Composition Analysis (2013–2024)
This chart breaks down Inventiva S.A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.96 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -21.09 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.05 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Inventiva S.A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Inventiva S.A (2013–2024)
The table below shows the annual total liabilities of Inventiva S.A from 2013 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $225.61 Million | +122.08% |
| 2023-12-31 | $101.59 Million | +44.04% |
| 2022-12-31 | $70.53 Million | +112.96% |
| 2021-12-31 | $33.12 Million | +19.53% |
| 2020-12-31 | $27.71 Million | +77.98% |
| 2019-12-31 | $15.57 Million | -14.54% |
| 2018-12-31 | $18.22 Million | +75.86% |
| 2017-12-31 | $10.36 Million | -21.15% |
| 2016-12-31 | $13.14 Million | -26.22% |
| 2015-12-31 | $17.81 Million | -17.67% |
| 2014-12-31 | $21.63 Million | -23.05% |
| 2013-12-31 | $28.11 Million | -- |